FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245186715> ?p ?o ?g. }

• W4245186715 endingPage "x28" @default.
• W4245186715 startingPage "x28" @default.
• W4245186715 abstract "Background: Eribulin is a non-taxane microtubule dynamics inhibitor that has been proven to prolong overall survival in patients with breast cancer. S-1, an oral anticancer drug, has demonstrated non-inferiority in overall survival (OS) to taxane as first-line chemotherapy for metastatic breast cancer (MBC). We previouly reported phase I trial results for the combination of these drugs with an overall response rate of 41.7% and median progression free survival (PFS) of 7.6 months. George W et.al (J Clin Oncol 2003) suggested that estrogen receptor negativity, the presence of three or more sites of disease, a short disease-free interval (1 to 24 months), and prior systemic therapy all predicted for impaired overall survival in their multivariate analysis. Considering these factors, we conducted a multicenter phase II study of this combination to further evaluate its safety and efficacy. Methods: Recurrent or advanced breast cancer patients previously treated with anthracycline or taxanes were enrolled from September 2014 to May 2016. Patients received Eribulin 1.4 mg/m2 day1 and day8 intravenously and S-1 50 mg/m2 from day1 to day14 orally. Primary objective was to investigate safety and efficacy. Secondary objectives were to evaluate PFS, OS and clinical benefit rate (CBR) using Response Criteria in Solid Tumors (RECIST). Results: Thirty-two patients were enrolled this trial and 30 patients were evaluable. Objective response rate was 36.7%. There were 3 [10%] complete responses, 8 [26.7%] partial responses and 11 [36.7%] stable diseases. This combination therapy had a manageable safety profiles consistent with the known adverse effects of both drugs. The most common grade3-4 adverse events were neutropenia (22 [73.3%] of 32 patients), leukopenia (13 [43.3%] of 32 patients), febrile neutropenia (3 [9.4%] of 32 patients) and peripheral neuropathy (4 [12.5%] of 32 patients). CBR was 46.7%. The median overall survival and the median PFS was not reached. Conclusions: We showed tolerability and clinical activity in this combination therapy in a subset of patients with poor prognosis. Eribulin in combination with S-1 may represent a promising treatment option for advanced or recurrent breast cancer patients. Legal entity responsible for the study: Eisai Funding: Eisai Disclosure: All authors have declared no conflicts of interest." @default.
• W4245186715 created "2022-05-12" @default.
• W4245186715 creator A5000595317 @default.
• W4245186715 creator A5007874609 @default.
• W4245186715 creator A5008577264 @default.
• W4245186715 creator A5012322249 @default.
• W4245186715 creator A5013808390 @default.
• W4245186715 creator A5016197648 @default.
• W4245186715 creator A5024261346 @default.
• W4245186715 creator A5027604120 @default.
• W4245186715 creator A5035431011 @default.
• W4245186715 creator A5038588933 @default.
• W4245186715 creator A5039259135 @default.
• W4245186715 creator A5039576135 @default.
• W4245186715 creator A5041726660 @default.
• W4245186715 creator A5043782560 @default.
• W4245186715 creator A5053300812 @default.
• W4245186715 creator A5057484991 @default.
• W4245186715 creator A5058195283 @default.
• W4245186715 creator A5059656591 @default.
• W4245186715 creator A5078585781 @default.
• W4245186715 creator A5079556027 @default.
• W4245186715 date "2017-11-01" @default.
• W4245186715 modified "2023-09-26" @default.
• W4245186715 title "Phase II trial of eribulin and S-1 combination therapy for advanced or recurrent breast cancer" @default.
• W4245186715 doi "https://doi.org/10.1093/annonc/mdx654.005" @default.
• W4245186715 hasPublicationYear "2017" @default.
• W4245186715 type Work @default.
• W4245186715 citedByCount "0" @default.
• W4245186715 crossrefType "journal-article" @default.
• W4245186715 hasAuthorship W4245186715A5000595317 @default.
• W4245186715 hasAuthorship W4245186715A5007874609 @default.
• W4245186715 hasAuthorship W4245186715A5008577264 @default.
• W4245186715 hasAuthorship W4245186715A5012322249 @default.
• W4245186715 hasAuthorship W4245186715A5013808390 @default.
• W4245186715 hasAuthorship W4245186715A5016197648 @default.
• W4245186715 hasAuthorship W4245186715A5024261346 @default.
• W4245186715 hasAuthorship W4245186715A5027604120 @default.
• W4245186715 hasAuthorship W4245186715A5035431011 @default.
• W4245186715 hasAuthorship W4245186715A5038588933 @default.
• W4245186715 hasAuthorship W4245186715A5039259135 @default.
• W4245186715 hasAuthorship W4245186715A5039576135 @default.
• W4245186715 hasAuthorship W4245186715A5041726660 @default.
• W4245186715 hasAuthorship W4245186715A5043782560 @default.
• W4245186715 hasAuthorship W4245186715A5053300812 @default.
• W4245186715 hasAuthorship W4245186715A5057484991 @default.
• W4245186715 hasAuthorship W4245186715A5058195283 @default.
• W4245186715 hasAuthorship W4245186715A5059656591 @default.
• W4245186715 hasAuthorship W4245186715A5078585781 @default.
• W4245186715 hasAuthorship W4245186715A5079556027 @default.
• W4245186715 hasBestOaLocation W42451867151 @default.
• W4245186715 hasConcept C121608353 @default.
• W4245186715 hasConcept C126322002 @default.
• W4245186715 hasConcept C141071460 @default.
• W4245186715 hasConcept C143998085 @default.
• W4245186715 hasConcept C2775930923 @default.
• W4245186715 hasConcept C2776387010 @default.
• W4245186715 hasConcept C2776694085 @default.
• W4245186715 hasConcept C2776802502 @default.
• W4245186715 hasConcept C2776999253 @default.
• W4245186715 hasConcept C2777511904 @default.
• W4245186715 hasConcept C2779984678 @default.
• W4245186715 hasConcept C2780739268 @default.
• W4245186715 hasConcept C31760486 @default.
• W4245186715 hasConcept C530470458 @default.
• W4245186715 hasConcept C535046627 @default.
• W4245186715 hasConcept C71924100 @default.
• W4245186715 hasConceptScore W4245186715C121608353 @default.
• W4245186715 hasConceptScore W4245186715C126322002 @default.
• W4245186715 hasConceptScore W4245186715C141071460 @default.
• W4245186715 hasConceptScore W4245186715C143998085 @default.
• W4245186715 hasConceptScore W4245186715C2775930923 @default.
• W4245186715 hasConceptScore W4245186715C2776387010 @default.
• W4245186715 hasConceptScore W4245186715C2776694085 @default.
• W4245186715 hasConceptScore W4245186715C2776802502 @default.
• W4245186715 hasConceptScore W4245186715C2776999253 @default.
• W4245186715 hasConceptScore W4245186715C2777511904 @default.
• W4245186715 hasConceptScore W4245186715C2779984678 @default.
• W4245186715 hasConceptScore W4245186715C2780739268 @default.
• W4245186715 hasConceptScore W4245186715C31760486 @default.
• W4245186715 hasConceptScore W4245186715C530470458 @default.
• W4245186715 hasConceptScore W4245186715C535046627 @default.
• W4245186715 hasConceptScore W4245186715C71924100 @default.
• W4245186715 hasLocation W42451867151 @default.
• W4245186715 hasOpenAccess W4245186715 @default.
• W4245186715 hasPrimaryLocation W42451867151 @default.
• W4245186715 hasRelatedWork W2288051007 @default.
• W4245186715 hasRelatedWork W2325706841 @default.
• W4245186715 hasRelatedWork W2588567008 @default.
• W4245186715 hasRelatedWork W2612052752 @default.
• W4245186715 hasRelatedWork W2613657120 @default.
• W4245186715 hasRelatedWork W2886394532 @default.
• W4245186715 hasRelatedWork W2980732823 @default.
• W4245186715 hasRelatedWork W3160156778 @default.
• W4245186715 hasRelatedWork W4205779066 @default.
• W4245186715 hasRelatedWork W4322771556 @default.
• W4245186715 hasVolume "28" @default.
• W4245186715 isParatext "false" @default.

• next